These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34019619)

  • 21. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.
    Gangadharan B; Delignat S; Ollivier V; Gupta N; Mackman N; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2014 Dec; 12(12):2065-9. PubMed ID: 25267332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII.
    Zakas PM; Healey JF; Smith IW; Lillicrap D; Lollar P
    Front Immunol; 2020; 11():150. PubMed ID: 32117290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.
    Zerra PE; Cox C; Baldwin WH; Patel SR; Arthur CM; Lollar P; Meeks SL; Stowell SR
    Blood; 2017 Dec; 130(23):2559-2568. PubMed ID: 28978569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
    Meeks SL; Cox CL; Healey JF; Parker ET; Doshi BS; Gangadharan B; Barrow RT; Lollar P
    Blood; 2012 Sep; 120(12):2512-20. PubMed ID: 22855607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
    Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
    Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Retrospective Study of the Cytokine Profile Changes in Mice with FVIII Inhibitor Development After Adeno-Associated Virus-Mediated Gene Therapy in a Hemophilia A Mouse Model.
    Sun J; Yuan Z; Abajas YL; Szollosi DE; Hu G; Hua B; Xiao X; Li C
    Hum Gene Ther; 2018 Mar; 29(3):381-389. PubMed ID: 28922951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and characterization of recombinant murine factor VIII.
    Doering C; Parker ET; Healey JF; Craddock HN; Barrow RT; Lollar P
    Thromb Haemost; 2002 Sep; 88(3):450-8. PubMed ID: 12353075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia A.
    Roth SD; Schüttrumpf J; Milanov P; Abriss D; Ungerer C; Quade-Lyssy P; Simpson JC; Pepperkok R; Seifried E; Tonn T
    PLoS One; 2012; 7(9):e44505. PubMed ID: 22973456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.
    Abdel-Motal U; Wang S; Lu S; Wigglesworth K; Galili U
    J Virol; 2006 Jul; 80(14):6943-51. PubMed ID: 16809300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
    Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerating Factor VIII: Recent Progress.
    Lacroix-Desmazes S; Voorberg J; Lillicrap D; Scott DW; Pratt KP
    Front Immunol; 2019; 10():2991. PubMed ID: 31998296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro.
    Werwitzke S; Vollack N; von Hornung M; Kalippke K; Kutzschbach J; Trummer A; Ganser A; Tiede A
    Thromb Haemost; 2015 Nov; 114(6):1127-35. PubMed ID: 26245154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries.
    Schmidt A; Brettschneider K; Kahle J; Orlowski A; Becker-Peters K; Stichel D; Schulze J; Braner M; Tampé R; Schwabe D; Königs C
    Thromb Haemost; 2016 Jul; 116(1):32-41. PubMed ID: 27009573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells.
    Pohl AP; Venkatesha SH; Zhang AH; Scott DW
    Front Immunol; 2020; 11():693. PubMed ID: 32373126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in knowledge of inhibitor formation in severe haemophilia A.
    Cormier M; Batty P; Tarrant J; Lillicrap D
    Br J Haematol; 2020 Apr; 189(1):39-53. PubMed ID: 32064603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.